Our Work
Latham & Watkins Advises Revolution Medicines on US$2 Billion Growth Financing With Royalty Pharma
June 24, 2025
Multidisciplinary team represents the oncology company on one of the largest royalty, structured debt, growth financing, and private capital financings in the life sciences space.
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, has announced that it has partnered with Royalty Pharma on a US$2 billion financing — royalty and structured debt — to support Revolution Medicines’ independent global development and commercialization strategy and operations.
Latham & Watkins LLP represents long-time client Revolution Medicines with a transactional deal team led by partners Haim Zaltzman, Mark Roeder, Elizabeth Oh, and John Williams, and counsel Benjamin Gelfand, with associates Andrew Miller, Kendall Ota, Zuza Gruca, Bridget Carmody, and Eduardo Magana. Advice was also provided on intellectual property matters by counsel Robert Yeh, with associates Kristina Funahashi and Patrick Chew; on tax advice by partner Eric Cho, with associate Jeremiah Cowen; on security matters by partner Brian Rock and counsel Emily Leong Yu, with paralegal Rhonda Deleon; and on securitization matters by partners Matthew Hays, Jim Fogarty, and Kimberly Posin.